(Q37854715)

24 August 2017

1 reference

title

New drug therapies in peripheral T-cell lymphoma (English)

1 reference

24 August 2017

1 reference

ChEBI release 2020-05-28

Rebecca A Howman

1

1 reference

24 August 2017

H Miles Prince

series ordinal

2

1 reference

24 August 2017

publication date

1 March 2011

1 reference

Expert Review of Anticancer Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

457-472

1 reference

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

24 August 2017

cites work

1 reference

Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets.

21 January 2018

1 reference

Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification

21 January 2018

1 reference

Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience

21 January 2018

1 reference

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

21 January 2018

1 reference

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

21 January 2018

1 reference

Novel therapies and role of transplant in the treatment of peripheral T-cell lymphomas

21 January 2018

1 reference

Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression.

21 January 2018

1 reference

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

21 January 2018

1 reference

Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

21 January 2018

1 reference

A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodgkin's or Hodgkin's lymphoma.

21 January 2018

1 reference

Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies

21 January 2018

1 reference

Chromatin modification, leukaemia and implications for therapy.

21 January 2018

1 reference

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

21 January 2018

1 reference

Anticancer activities of histone deacetylase inhibitors

21 January 2018

1 reference

Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor

21 January 2018

1 reference

Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies

21 January 2018

1 reference

Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications

21 January 2018

1 reference

Clinical studies of histone deacetylase inhibitors.

21 January 2018

1 reference

Histone deacetylase inhibitors in lymphoma and solid malignancies

21 January 2018

1 reference

Epigenetic modifiers: basic understanding and clinical development.

21 January 2018

1 reference

The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis

21 January 2018

1 reference

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma

21 January 2018

1 reference

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma

21 January 2018

1 reference

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity

21 January 2018

1 reference

Treatment of refractory T-cell malignancies using gemcitabine

21 January 2018

1 reference

Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.

21 January 2018

1 reference

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

21 January 2018

1 reference

Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma

21 January 2018

1 reference

Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes

21 January 2018

1 reference

Current status of older and new purine nucleoside analogues in the treatment of lymphoproliferative diseases.

21 January 2018

1 reference

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

21 January 2018

1 reference

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

21 January 2018

1 reference

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas

21 January 2018

1 reference

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

21 January 2018

1 reference

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome

21 January 2018

1 reference

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

21 January 2018

1 reference

Alemtuzumab and DHAP (A-DHAP) is effective for relapsed peripheral T-cell lymphoma, unspecified: interim results of a phase II prospective study

21 January 2018

1 reference

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies

21 January 2018

1 reference

Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy

21 January 2018

1 reference

Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab

21 January 2018

1 reference

21 January 2018

1 reference

Interleukin 2 receptor-targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells.

21 January 2018

1 reference

Effects of the proteasome inhibitor PS-341 on tumor growth in HTLV-1 Tax transgenic mice and Tax tumor transplants

21 January 2018

1 reference

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma

21 January 2018

1 reference

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

21 January 2018

1 reference

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

21 January 2018

1 reference

Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes

21 January 2018

1 reference

Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy

21 January 2018

1 reference

Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas.

21 January 2018

1 reference

Distinguishing angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified, using morphology, immunophenotype and molecular genetics

21 January 2018

1 reference

Advances in the understanding and management of angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

Angioimmunoblastic T-cell lymphoma.

21 January 2018

1 reference

Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials

21 January 2018

1 reference

Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation

21 January 2018

1 reference

Pathology and clinical features of angioimmunoblastic T-cell lymphoma after successful treatment with thalidomide

21 January 2018

1 reference

Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: two case reports

21 January 2018

1 reference

Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy

21 January 2018

1 reference

A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.

21 January 2018

1 reference

Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma.

21 January 2018

1 reference

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project

21 January 2018

1 reference

Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan

21 January 2018

1 reference

Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study

21 January 2018

1 reference

In situ depletion of CD4+ T cells in human skin by Zanolimumab

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.11.4

1 reference

24 August 2017

1 reference